Recombinant SARS-CoV-2 Nucleocapsid anticorps (Whole Molecule)

N° du produit ABIN7581774

L’anticorps Souris Monoclonal anti-SARS-CoV-2 Nucleocapsid a été validé pour ELISA, WB, IF et FACS. Il convient pour détecter SARS-CoV-2 Nucleocapsid dans des échantillons de SARS Coronavirus-2 (SARS-CoV-2).

Aperçu rapide pour Recombinant SARS-CoV-2 Nucleocapsid anticorps (Whole Molecule) (ABIN7581774)

Antigène: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Type d'anticorp: Recombinant Antibody

Reactivité: SARS Coronavirus-2 (SARS-CoV-2)

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp SARS-CoV-2 Nucleocapsid est non-conjugé

Application: ELISA, Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS)

Classe de qualité: Animal-Free

Clone: AB79-E11

Détail du produit anti-SARS-CoV-2 Nucleocapsid anticorps

Épitope: Whole Molecule

Expression System: Phage display

Fonction: recombinant anti-SARS-CoV-2 Nucleocapsid protein antibody

Specificité: This is an antibody developed by antibody phage display technology using a human naive antibody gene library and SARS-CoV-2 antigen. For this antibody both the heavy and light chains are cloned and expressed, generating full-length antibodies.

Réactivité croisée (Details): SARS-CoV1 N-protein

Attributs du produit: This antibody can be detected with anti-mouse Fc secondary antibodies.

Purification: Protein A purification

Immunogène: No immunization, animal-free antibody development. Antigen: Nucleocapsid protein: MSDNGPQSNQRSAPRITFGGPTDSTDNNQNGGRNGARPKQRRPQGLPNNTASWFTALTQHGKEELRFPRGQGVPINTNSGPDDQIGYYRRATRRVRGGDGKMKELSPRWYFYYLGTGPEASLPYGANKEGIVWVATEGALNTPKDHIGTRNPNNNAATVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRGNSRNSTPGSSRGNSPARMASGGGETALALLLLDRLNQLESKVSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKQYNVTQAFGRRGPEQTQGNFGDQDLIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYHGAIKLDDKDPQFKDNVILLNKHIDAYKTFPPTEPKKDKKKKTDEAQPLPQRQKKQPTVTLLPAADMDDFSRQLQNSMSGASADSTQA

Isotype: IgG2a

Information d'application

Indications d'application: Western Blot: 0.2-5 μg/mL ELISA: 1-12 μg/mL as coating antibody 0.5-5 μg/mL as detection antibody IF: 0.1 - 10 μg/mL Optimal working dilution should be determined by the investigator

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4,

Stock: -20 °C

Détails sur SARS-CoV-2 Nucleocapsid

Antigène: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Autre désignation: SARS-CoV-2 Nucleocapsid protein (NP)

Sujet: Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome β-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD) and a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that could inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.

Poids moléculaire: 25 kDa

NCBI Accession: NP_828858

UniProt: P59595